- Twist Bioscience Corporation TWST has announced a broad-based research collaboration with Boehringer Ingelheim International GmbH.
- The collaboration will use Twist's proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.
- Boehringer Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration.
- Twist will receive an upfront payment for each program entry. In addition, Twist can earn up to $710 million in milestone payments for the multiple target discovery programs.
- Price Action: TWST shares are up 7.50% at $119.32 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
